A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Alsevalimab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Ovarian cancer; Peritoneal cancer; Salivary gland cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer; Uterine cancer
- Focus Adverse reactions; First in man
- Sponsors Five Prime Therapeutics
- 06 Jan 2022 Status changed from active, no longer recruiting to completed.
- 30 Apr 2021 Planned End Date changed from 1 Jan 2024 to 1 Jan 2022.
- 30 Apr 2021 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2022.